CalciMedica's 2025 Financial Results and Promising Clinical Updates on Novel Therapies CalciMedica Inc. has reported its financial results for 2025 while providing significant updates on its clinical trials, including promising therapies for acute kidney injury and pancreatitis.

CalciMedica's 2025 Financial Results and Promising Clinical Updates on Novel Therapies #USA #La_Jolla #CalciMedica #Auxora #CM5480

CalciMedica Halts KOURAGE Clinical Trial Amid Safety Concerns CalciMedica Inc. has announced the discontinuation of its Phase 2 KOURAGE trial evaluating Auxora™ in AKI patients due to safety concerns highlighted by the Independent Data Monitoring Committee.

CalciMedica Halts KOURAGE Clinical Trial Amid Safety Concerns #United_States #La_Jolla #CalciMedica #Auxora #KOURAGE

CalciMedica Reveals Q3 2025 Financial Performance and Promising Clinical Progress CalciMedica reports financial results for Q3 2025 alongside crucial updates on its clinical trials and development projects, indicating positive progress.

CalciMedica Reveals Q3 2025 Financial Performance and Promising Clinical Progress #United_States #La_Jolla #CalciMedica #Auxora #AKI

CalciMedica Partners with Telperian to Enhance Clinical Trials with AI Technology CalciMedica teams up with Telperian to leverage AI for analyzing clinical trial data, optimizing outcomes for AuxoraTM treatment.

CalciMedica Partners with Telperian to Enhance Clinical Trials with AI Technology #USA #La_Jolla #CalciMedica #Auxora #Telperian

CalciMedica to Present at H.C. Wainwright 27th Global Investment Conference 2025 CalciMedica, a biopharmaceutical company, will showcase its CRAC channel inhibition therapies at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025.

CalciMedica to Present at H.C. Wainwright 27th Global Investment Conference 2025 #CalciMedica #Auxora #CRAC_channel

CalciMedica Provides Financial and Clinical Updates for Q2 2025 CalciMedica Inc. reports Q2 2025 financial results, ongoing trials, and corporate developments, highlighting progress in treatments for acute kidney injury.

CalciMedica Provides Financial and Clinical Updates for Q2 2025 #United_States #La_Jolla #CalciMedica #Auxora #AKI

CalciMedica CEO to Speak at H.C. Wainwright's Kidney Virtual Conference on Innovations in CRAC Channel Therapies CalciMedica will be presenting at the upcoming H.C. Wainwright Virtual Conference, focusing on novel therapies for inflammatory conditions.

CalciMedica CEO to Speak at H.C. Wainwright's Kidney Virtual Conference on Innovations in CRAC Channel Therapies #CalciMedica #Auxora #CRAC_channel

CalciMedica Unveils Insights from KOURAGE Trial in American Journal of Nephrology CalciMedica Inc. announces a publication detailing the Phase 2 KOURAGE trial design for Auxora in treating AKI with respiratory failure, featured in the American Journal of Nephrology.

CalciMedica Unveils Insights from KOURAGE Trial in American Journal of Nephrology #USA #La_Jolla #CalciMedica #Auxora #KOURAGE_Trial

CalciMedica to Host Symposium on Novel Therapies for Acute Kidney Injury at Vicenza Course 2025 CalciMedica will present advancements in calcium release-activated therapies at an upcoming symposium during the 43rd Vicenza Course on Critical Care Nephrology in Italy.

CalciMedica to Host Symposium on Novel Therapies for Acute Kidney Injury at Vicenza Course 2025 #United_States #La_Jolla #CalciMedica #Auxora #CRAC

CalciMedica Makes Significant Progress in Novel Biopharmaceutical Development Amid Q1 Financial Results CalciMedica Inc. reports encouraging developments for its biopharmaceutical pipeline and strong financial backing as of Q1 2025.

CalciMedica Makes Significant Progress in Novel Biopharmaceutical Development Amid Q1 Financial Results #United_States #La_Jolla #CalciMedica #Auxora #AKI

CalciMedica Set to Showcase Innovative Research at Medical Conferences CalciMedica announces key presentations at prestigious medical meetings, showcasing their advancements in therapies for immune-related conditions.

CalciMedica Set to Showcase Innovative Research at Medical Conferences #United_States #La_Jolla #CalciMedica #Auxora #CRAC_channels

CalciMedica Obtains $32.5 Million Credit Facility to Advance Novel Therapies CalciMedica Inc. secures a $32.5 million credit facility to enhance its product pipeline, providing crucial funding into 2026 for innovative therapies.

CalciMedica Obtains $32.5 Million Credit Facility to Advance Novel Therapies #United_States #La_Jolla #CalciMedica #Auxora #Avenue_Capital

CalciMedica Shares Promising AKI Data on Auxora at International Conference CalciMedica Inc. presented new findings from the CARDEA trial on its treatment Auxora for severe COVID-19 pneumonia, showcasing significant mortality reduction in AKI patients.

CalciMedica Shares Promising AKI Data on Auxora at International Conference #United_States #San_Diego #COVID-19 #CalciMedica #Auxora

CalciMedica to Showcase Innovations in AKI Prevention at Key Medical Conference CalciMedica Inc. announces a key presentation on their novel therapies for AKI at the upcoming conference in San Diego. Learn more about their innovative research.

CalciMedica to Showcase Innovations in AKI Prevention at Key Medical Conference #United_States #La_Jolla #CalciMedica #Auxora #AKI

CalciMedica Welcomes Dr. Alan Glicklich to Board of Directors on January 15, 2025 CalciMedica has appointed Dr. Alan Glicklich to its Board of Directors, enhancing its expertise as it advances critical clinical trials for therapies.

CalciMedica Welcomes Dr. Alan Glicklich to Board of Directors on January 15, 2025 #USA #La_Jolla #CalciMedica #Auxora #Alan_Glicklich